SCHEMBL2485548

SCHEMBL2485548

Cc1nccn1-c1ccc(Nc2nc3c(c(Cc4ccc(F)cc4)n2)CSCC3)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 2/20 0.38
NR3C2 P08235 3/20 0.37
STAT6 P42226 1/20 0.33
ALOX5 P09917 4/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
KCNH2 Q12809 1/20 0.33
TP53 P04637 1/20 0.33
THRB P10828 1/20 0.33
KCNH3 Q9ULD8 3/20 0.32
ALDH1A1 P00352 1/20 0.32
JAK2 O60674 1/20 0.32
TUBB4A P04350 1/20 0.32
TUBB P07437 1/20 0.32
TUBA3C P0DPH7 1/20 0.32
TUBA1B P68363 1/20 0.32
TUBA4A P68366 1/20 0.32
TUBB4B P68371 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2480381 0.91 CYP3A4 (0.36) EGFRNR3C2CYP3A4CYP2D6CYP2C9
SCHEMBL2473812 0.83 EGFR (0.37) EGFRNR3C2STAT6ALOX5CYP3A4
SCHEMBL2447600 0.82 EGFR (0.37) EGFRNR3C2STAT6ALOX5TP53
SCHEMBL2445284 0.81 JAK2 (0.36) CYP3A4CYP2D6CYP2C9CYP2C19KCNH2
SCHEMBL2446341 0.77 ROCK2 (0.40) EGFRCYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL2482372 0.77 TUBB4A (0.37) EGFRSTAT6CYP3A4CYP2D6CYP2C9
SCHEMBL2478896 0.76 STAT6 (0.37) NR3C2STAT6CYP3A4CYP2D6ALDH1A1
SCHEMBL2480019 0.76 ROCK2 (0.43) EGFRSTAT6CYP3A4CYP2D6CYP2C9
SCHEMBL2480963 0.76 HTR2C (0.39) CYP3A4CYP2D6CYP2C9CYP2C19ALDH1A1
SCHEMBL2481514 0.74 CYP3A4 (0.35) NR3C2STAT6CYP3A4CYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8188101-B2 Dihydropyridopyrimidines for the treatment of AB-related pathologies ASTRAZENECA AB (SE) 2012-05-29 US disclosed
US-8188101-B2 Dihydropyridopyrimidines for the treatment of AB-related pathologies ASTRAZENECA AB (SE) 2012-05-29 US disclosed
US-8188101-B2 Dihydropyridopyrimidines for the treatment of AB-related pathologies ASTRAZENECA AB (SE) 2012-05-29 US disclosed
EP-2367826-A1 MODULATORS OF AMYLOID BETA. AstraZeneca AB (SE) 2011-09-28 EP disclosed
US-20100130495-A1 COMPOUNDS 563 ASTRAZENECA AB (SE) 2010-05-27 US disclosed
US-20100130495-A1 COMPOUNDS 563 ASTRAZENECA AB (SE) 2010-05-27 US disclosed
US-20100130495-A1 COMPOUNDS 563 ASTRAZENECA AB (SE) 2010-05-27 US disclosed
WO-2010053438-A1 MODULATORS OF AMYLOID BETA. ASTRAZENECA AB (SE) 2010-05-14 WO disclosed
WO-2010053438-A1 MODULATORS OF AMYLOID BETA. ASTRAZENECA AB (SE) 2010-05-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130495-A1 COMPOUNDS 563 BACE1, PSEN1, PSEN2 EGFR 2791/4885NR3C2 2599/4885STAT6 3493/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.